Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's your opinion. Did you give them a call?
I see many green flags!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111656318
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111656237
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111656133
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111656023
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111655813
I see many red flags!
Quote:
Yes, I concur. However, to be a 'lasting CFO' at NNVC you got to be 'ALL IN' on the scam. A independent CFO could balk at some of the machinations. Well, you can't have that. Besides when your as greedy a Diwan is, you always need more $'s. As he knows better than most, that it won't last much longer.
-bunny-
Quote:
I have to say one of the biggest red flags for me is when Dr. Diwan made his wife CFO. That stinks like a dead fish. You can argue for the competence of Meeta Vyas all you like, the fact remains that there are thousands of other competent financial people any one of which could have been hired as CFO and who weren't married to Dr. Diwan.
Yes, I concur. However, to be a 'lasting CFO' at NNVC you got to be 'ALL IN' on the scam. A independent CFO could balk at some of the machinations. Well, you can't have that. Besides when your as greedy a Diwan is, you always need more $'s. As he knows better than most, that it won't last much longer.
-bunny-
Quote:
I have to say one of the biggest red flags for me is when Dr. Diwan made his wife CFO. That stinks like a dead fish. You can argue for the competence of Meeta Vyas all you like, the fact remains that there are thousands of other competent financial people any one of which could have been hired as CFO and who weren't married to Dr. Diwan.
An NNVC SPRING.................
With a beautiful summer.
What do I think;
NNVC will succeed with FluCide and other drugs to come.
The stock will be far beyond what we can imagine.
FN
NNVC is becoming increasingly recognized in the stock market world :
BLACKROCK FUND ADVISORS
12/31/2014 1,179,960 232,570 24.55 3,056
VANGUARD GROUP INC
12/31/2014 1,110,560 29,478 2.73 2,876
NORTHERN TRUST CORP
12/31/2014 426,716 784 .18 1,105
STATE STREET CORP
12/31/2014 420,435 37,908 9.91 1,089
BARCLAYS GLOBAL INVESTORS UK HOLDINGS LTD
12/31/2014 362,433 (1,292) (0.36) 939
GEODE CAPITAL MANAGEMENT, LLC
12/31/2014 210,570 6,039 2.95 545
KCG HOLDINGS, INC.
12/31/2014 201,209 181,459 918.78 521
BRIDGEWAY CAPITAL MANAGEMENT INC
12/31/2014 197,500 54,500 38.11 512
BANK OF NEW YORK MELLON CORP
12/31/2014 169,622 (3,089) (1.79) 439
TIAA CREF INVESTMENT MANAGEMENT LLC
12/31/2014 142,257 (6,943) (4.65) 368
BLACKROCK INVESTMENT MANAGEMENT, LLC
12/31/2014 123,995 7,512 6.45 321
GOLDMAN SACHS GROUP INC
12/31/2014 88,324 (42,607) (32.54) 229
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
12/31/2014 79,736 6,116 8.31 207
STONERIDGE INVESTMENT PARTNERS LLC
12/31/2014 77,158 16,267 26.72 200
DEUTSCHE BANK AG\
12/31/2014 67,984 7,570 12.53 176
SUSQUEHANNA INTERNATIONAL GROUP, LLP
12/31/2014 66,734 9,474 16.55 173
STALEY CAPITAL ADVISERS INC
12/31/2014 60,000 0 0.00 155
SCHWAB CHARLES INVESTMENT MANAGEMENT INC
12/31/2014 58,800 0 0.00 152
TEACHERS ADVISORS INC
12/31/2014 55,430 0 0.00 144
AQR CAPITAL MANAGEMENT LLC
12/31/2014 48,700 (33,400) (40.68) 126
UBS GROUP AG
12/31/2014 45,917 3,098 7.24 119
MORGAN STANLEY
12/31/2014 45,245 18,620 69.93 117
BARTLETT & CO. LLC
12/31/2014 40,714 0 0.00 105
VOYA INVESTMENT MANAGEMENT LLC
12/31/2014 39,869 0 0.00 103
NATIONWIDE FUND ADVISORS
12/31/2014 33,002 2,444 8.00 85
RHUMBLINE ADVISERS
12/31/2014 29,365 975 3.43 76
FERGUSON WELLMAN CAPITAL MANAGEMENT, INC
12/31/2014 28,572 0 0.00 74
RATHBONE BROTHERS PLC
12/31/2014 28,250 0 0.00 73
D. E. SHAW & CO., INC.
12/31/2014 27,006 27,006 New 70
AMERICAN INTERNATIONAL GROUP INC
12/31/2014 26,475 (958) (3.49) 69
RENAISSANCE TECHNOLOGIES LLC
12/31/2014 18,471 18,471 New 48
STANCORP INVESTMENT ADVISERS INC
12/31/2014 18,000 18,000 New 47
RNC CAPITAL MANAGEMENT LLC
12/31/2014 17,143 0 0.00 44
BLACKROCK ADVISORS LLC
12/31/2014 16,944 0 0.00 44
BANK OF AMERICA CORP /DE/
12/31/2014 12,201 7,905 184.01 32
WELLS FARGO & COMPANY/MN
12/31/2014 8,361 1,013 13.79 22
CITIGROUP INC
12/31/2014 7,358 5,700 343.79 19
SANDY SPRING BANK
12/31/2014 6,414 3,100 93.54 17
ROYAL BANK OF CANADA
12/31/2014 6,042 5,000 479.85 16
NORTH STAR INVESTMENT MANAGEMENT CORP.
12/31/2014 6,000 0 0.00 16
MANUFACTURERS LIFE INSURANCE COMPANY, THE
12/31/2014 5,854 (20,111) (77.45) 15
SIMPLEX TRADING, LLC
12/31/2014 4,442 4,442 New 12
GROUP ONE TRADING, L.P.
12/31/2014 3,773 3,773 New 10
BANK OF MONTREAL /CAN/
12/31/2014 3,407 550 19.25 9
LADENBURG THALMANN FINANCIAL SERVICES INC
12/31/2014 2,866 0 0.00 7
REGENTATLANTIC CAPITAL LLC
12/31/2014 2,858 2,858 New 7
ALLIANCEBERNSTEIN L.P.
12/31/2014 2,800 0 0.00 7
BARCLAYS PLC
12/31/2014 2,441 669 37.75 6
CREATIVE PLANNING
12/31/2014 2,286 0 0.00 6
DAVIDSON D A & CO
12/31/2014 1,886 0 0.00 5
TOWER RESEARCH CAPITAL LLC (TRC)
12/31/2014 1,772 (20,414) (92.01) 5
PINNACLE SUMMER INVESTMENTS, INC.
12/31/2014 286 0 0.00 1
US BANCORP \DE\
12/31/2014 86 0 0.00
BLUECREST CAPITAL MANAGEMENT LLP
06/30/2014 0 (58,400) Sold Out
BNP PARIBAS ARBITRAGE, SA
12/31/2014 0 (2,417) Sold Out
CITADEL ADVISORS LLC
12/31/2014 0 (8,091) Sold Out
COLONY GROUP LLC
12/31/2014 0 (85,724) Sold Out
JACOBS LEVY EQUITY MANAGEMENT, INC
12/31/2014 0 (16,700) Sold Out
PROSHARE ADVISORS LLC
12/31/2014 0 (15,930) Sold Out
WEATHERLY ASSET MANAGEMENT L. P.
12/31/2014 0 (42,644) Sold Out
NNVC is exhibited increasingly with a "strong buy":
NanoViricides Announces that a Research Report on the Company has been Published By Midtown Partners, Inc., a New York Invest...[/b
WEST HAVEN, Conn., Feb. 17, 2015 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, reported that Midtown Partners, Inc., ("Midtown") has published a research report on NanoViricides on February 11, 2014, according to Midtown's website. The report can be found on their website at http://www.midtownpartners.com under the "Research" tab.
Midtown initiated research coverage with a "Strong Buy" rating on NanoViricides with this report. The Company did not pay Midtown any fees or commissions for this research report. Previously, the banking arm of Midtown Partners has helped raise financing for NanoViricides in various investment banking engagements, wherein Midtown earned and was paid commissions and/or fees according to the appropriate engagement agreements in force, most recently in January 2014. Chardan Capital Markets, LLC, acted as lead placement agent and Midtown Partners was the co-placement agent in connection with this January 2014 registered direct offering.
Midtown's research analysts interviewed NanoViricides' executives for this report. Midtown research analysts also performed substantial additional independent research.
The Company does not comment on, and does neither endorse nor dispute any such third party research.
Remember that PR before the results from BASI:
NanoViricides Says Injectable FluCide™ Selected in Top Ten Project to Watch - Presentation Today at the Therapeutics Area P...
Print
Alert
NanoViricides, Inc. (AMEX:NNVC)
Historical Stock Chart
6 Months : From Sep 2014 to Mar 2015
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), announced today that its “Injectable FluCide™” drug candidate for severe influenza has been chosen as one of the “Top Ten Infectious Diseases Projects to Watch” by a panel of industry experts assembled by Informa and the publishers of In Vivo, Startup and The Pink Sheet. As a result of this selection, Anil R. Diwan, PhD, President and Chairman of the Company, will give a company presentation at the Therapeutic Area Partnerships Meeting taking place on November 19-21, 2014, at the Hyatt Regency Boston (www.tapartnerships.com). The presentation is scheduled for 4:20pm Eastern time, today, November 20, 2014.
[img]"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider among the most attractive opportunities the industry has to offer," said Marc Wortman, Editorial Director, Therapeutic Area Partnerships. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers.”
[/img]
The Company reports that all of its drug development programs are progressing satisfactorily and that it will continue to provide updates as appropriate.
In particular, the synthesis of anti-Ebola drug candidates is progressing satisfactorily. The Company has recently reported that it has signed a “Cooperative Research and Development Agreement - Materials Transfer Agreement (CRADA-MTA)” with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) for biological testing of these candidates. The Company is working expeditiously on its anti-Ebola program at present, in order to develop an effective drug candidate that may be available in response to the current Ebola epidemic crisis. The Company has the ability to produce sufficient quantities of a successful drug candidate for potential field use.
The Company has developed a state-of-the-art nanomedicines manufacturing facility that will be capable of producing any of the Company’s drug candidates in a cGMP-compliant manner in multi-kilogram quantities. This facility will be able to provide the cGMP clinical drug substances for the Company’s future human clinical studies. (“c-GMP”= current Good Manufacturing Practices). The Company’s Board of Directors has authorized acquisition of this facility from Inno-Haven, LLC, rather than leasing it. The acquisition process is in the due diligence phase at present, and is expected to be concluded soon.
Initial large animal safety/toxicology studies in the Company’s FluCide™ drug development program have begun at BASi, as previously reported. In addition, the Company is performing process development and scale up studies on its FluCide™ drug candidate in its existing facilities. The extremely high safety of FluCide has resulted in a very large quantity requirement for the GLP Safety/Toxicology studies, necessitating scale-up studies at this early stage.
The Company estimates that it now has approximately $42.6 Million (M) of current assets plus restricted cash in hand. The Company estimates that this funding is sufficient to enable us to perform initial human clinical trials of our injectable FluCide™ drug candidate, as well as possibly to advance our DengueCide™ orphan drug candidate towards initial human clinical trials. As previously reported, our strong cash position has enabled us to restart our anti-Ebola drug development program in response to the current epidemic. The Company’s estimates are based on its current rate of expenditure and also on certain approximate estimates for clinical development of its drug candidate as gleaned from discussions with various contract research organizations.
And that what's matter:
This study was developed in collaboration with BASi and conducted by BASi in a cGLP-like fashion in order to understand the safety parameters of FluCide intravenous dosing.
No direct adverse clinical effects were found upon administration of the FluCide candidate intravenously at doses of up to 300mg/kg/day for 14 days (a total of 4,200mg/kg) in rats.
2015 NNVC success is already started.
NanoViricides Reports that the FluCide® Candidate was found to be Very Safe in cGLP-like Safety and Toxicology Study in Rats...
Date : 01/23/2015 @ 7:00AM
Source : PR Newswire (US)
Stock : NanoViricides, Inc. (NNVC)
Quote : 2.61 0.03 (1.16%) @ 5:00PM
NanoViricides Reports that the FluCide® Candidate was found to be Very Safe in cGLP-like Safety and Toxicology Study in Rats...
Print
Alert
NanoViricides, Inc. (AMEX:NNVC)
Historical Stock Chart
2 Months : From Jan 2015 to Mar 2015
WEST HAVEN, Conn., Jan. 23, 2015 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, reported a good safety profile of an optimized FluCide® drug candidate in a GLP-like toxicology study in rats. These results are extremely important since they indicate that FluCide continues to look very promising as one of the most advanced candidates in the Company's drug development pipeline.
No direct adverse clinical effects were found upon administration of the FluCide candidate intravenously at doses of up to 300mg/kg/day for 14 days (a total of 4,200mg/kg) in rats.
Organs were examined for gross histological observations. Microscopic histological tissue analysis was also performed. There were no adverse histological findings in gross organ level histological examination, nor were there any adverse findings in microscopic histological analysis. Equally importantly, there were no meaningful effects observed on animal weight gain, food consumption, hematology, or clinical chemistry at the end of the 14 day dosing period.
The study was conducted at BASi (Bioanalytical Systems, Inc., NASDAQ: BASI) in Evansville, Indiana. The study was performed in a cGLP-like fashion, compliant with BASi Evansville standard operating procedures. BASi has over 40 years of experience providing contract research services and niche instrumentation to the life sciences, primarily drug research and development.
These results are in agreement with the previously reported results of a non-GLP toxicology study in mice. The current study results also support the Company's positive findings in animal models of infection with different influenza A virus strains in which no safety or toxicology concerns were observed. The Company has previously reported that many of its FluCide candidates demonstrated extremely high anti-influenza activity in those models.
This study was developed in collaboration with BASi and conducted by BASi in a cGLP-like fashion in order to understand the safety parameters of FluCide intravenous dosing.
The next phase of the toxicology package studies will involve larger animals, and will require much larger quantities of the drug candidate. The Company is in the process of commissioning operations at the new 1 Controls Drive, Shelton, CT facility in order to perform the scale up studies needed for making the large quantities of materials in a controlled manner. These upcoming studies will be performed in cGLP compliant manner to provide safety and toxicology data that are required for an IND submission to regulatory agencies.
Love Dr Seymour too:
Eugene Seymour M.D., MPH
Chief Executive Officer and Director, NanoViricides, Inc.
Age Total Calculated Compensation This person is connected to 9 board members in 1 different organizations across 1 different industries.
See Board Relationships
74 $462,387
As of Fiscal Year 2014
Background*
Dr. Eugene Seymour, M.D., MPH, has been the Chief Executive Officer of NanoViricides, Inc. since June 8, 2005. Dr. Seymour served as the Chief Financial Officer of NanoViricides, Inc. since June 8, 2005 and also served as its Principal Accounting Officer. Dr. Seymour served as an Interim Chief Financial Officer of NanoViricides, Inc. since May 16, 2007. Dr. Eugene Seymour, M.D., MPH, is a Managing Member at BioRevolution Capital Management LLC. He began clinical practice in Internal Medicine and joined the UCLA Medical School faculty. He Left UCLA after two years and joined USC faculty as Associate Professor. He served in the Medical Corps of United States Army Reserve during the Vietnam era and attained the rank of Major. He was originally trained as a chemist, but decided to attend medical school in preparation for a career as a clinical investigator. In 1981, Dr. Seymour began treating patients with a strange new disease affecting primarily the gay population. He worked with a number of celebrity patients whose identity could not be disclosed for fear of being ostracized in the entertainment community. In 1986, he was requested by the United States government to establish a testing laboratory and run a large-scale surveillance program for HIV prevalence in the Hispanic population in Los Angeles. In 1989, he founded Saliva Diagnostic Systems Inc.and served as its Chief Executive Officer and President since 1993. He left SDS in 1996 to form a non-profit foundation, which funded both testing and training programs for health workers in Asia and Africa. Dr. Seymour served as a Consultant to the United Nations Global Program on AIDS and was sent to a number of different countries, (Lithuania, Latvia, Estonia, and Russia) to interact with local physicians and assist them in setting up testing programs. He served as the Chairman of NanoViricides, Inc. since June 8, 2005 and has been its Director since June 1, 2005. He served as a Director of Strategic Alliances at a medical education startup called Medschool.com. Dr. Seymour spends his time as a private investor evaluating evolving companies in the field of biotechnology. He is the holder of 8 issued patents. Following postgraduate medical training, he holds a Master's degree in the Epidemiology of Infectious Diseases at UCLA.
Dr. Diwan purchased 14,000 shares in January at 2.56 per share and now owns over 2,000,000 shares. I don't know, but that doesn't sound like someone who's thinking the share price is going to tank.
So Diwan buys 14K shares? So what, that's nothing
I can't understand why anyone would think Seymour and Diwan are fraudsters.
Yes Weedie
I love it !!
I am waiting for the bloom responce.
Speculate!
Amazing!!
I hope nnvc will succeed with their moves to stop those atrocities.
http://search.yahoo.com/search;_ylt=A0LEV1weNvdUz14AARNXNyoA;_ylc=X1MDMjc2NjY3OQRfcgMyBGZyA2FhcGx3BGdwcmlkA29BeE9HajlSUTNhOUp4U0p1d2NSdUEEbl9yc2x0AzAEbl9zdWdnAzIEb3JpZ2luA3NlYXJjaC55YWhvby5jb20EcG9zAzAEcHFzdHIDBHBxc3RybAMEcXN0cmwDMzUEcXVlcnkDcGljdHVyZXMgb2YgcGVvcGxlIGR5aW5nIGZyb20gZWJvbGEEdF9zdG1wAzE0MjU0ODc0Mjg-?p=pictures+of+people+dying+from+ebola&fr2=sb-top-search&fr=aaplw
Sierra Leone’s vice president in quarantine for Ebola
By Clarence Roy-Macaulay, Associated Press
Sunday, March 1, 2015 | 7:01 p.m.
http://lasvegassun.com/news/2015/mar/01/sierra-leones-vice-president-quarantine-ebola/
FREETOWN, Sierra Leone — Sierra Leone's vice president has put himself in quarantine following the death from Ebola of one of his security guards.
Vice President Samuel Sam-Sumana is set to become acting president later Sunday when President Ernest Bai Koroma leaves Sierra Leone to attend a European Union conference on Ebola in Belgium. Sam-Sumana will carry out his presidential duties from his home.
He is the highest ranking African official to be in quarantine in this Ebola outbreak in West Africa, which is fast approaching a death toll of 10,000. The news highlights the rise of new cases in Sierra Leone, which has experienced a setback in curbing the spread of Ebola.
Sam-Sumana voluntarily decided to quarantine himself for 21 days following the death from Ebola last Tuesday of one of his security personnel.
"This virus has affected thousands of our people and has nearly brought our country to its knees," said Sam-Sumana in a statement on Sunday. "We all have a collective responsibility to break the chains of transmission by isolating the sick and reporting all known contacts, by not touching the dead ... We cannot be complacent. We must work together as a nation to end Ebola now."
Sam-Sumana's dramatic quarantine comes as President Ernest Bai Koroma reinstated restrictions on public movement on Saturday, in response the rise in new cases.
Sierra Leone recorded 18 new cases of Ebola in the week ending Saturday, up from 16 new cases last week. This breaks the trend of declining cases in the country.
Many of the new clusters are related to the capital's fishing industry. In one case a fisherman died at sea in early February and the boat returned his body to shore in Freetown, the capital. Some of the fishermen on the boat then returned to their homes in the shantytown surrounding the fishing wharf, causing new infections.
President Koroma had recently lifted travel restrictions in order to stimulate economic activity, a relaxation criticized as too early by some officials. In response to the rise in new cases, Koroma on Saturday re-imposed restrictions including a nighttime ban on all boats launching from shore and on commercial vehicles off-loading goods in western market areas. Naval vessels will enforce the measures by patrolling the wharves and coastline.
In addition there will be restrictions on ferries and health checkpoints by the police will be strengthened. Public transportation restrictions will be reinstated which limit the numbers of passengers in taxis to two in cars and four at the back of large taxi vans to reduce physical contact between passengers.
The death toll for the current Ebola outbreak has risen to more than 9,600 from more than 23,800 infections mostly in Guinea, Liberia and Sierra Leone, according to World Health Organization figures released Friday.
Liberia, which has had the highest number of deaths, has succeeded in bringing its number of confirmed cases to just a handful and has reopened schools.
Ebola is currently spreading fastest in Sierra Leone. In addition to battling Ebola, Sierra Leone's government last week launched an investigation after an audit showed that nearly one-third of the money it received to fight Ebola, about $5.7 million, was used without necessary receipts.
WORD OF MOUTH
http://news.yahoo.com/africas-medicine-men-key-halting-ebola-spread-guinea-061807365.html;_ylt=AwrBT9JCIvRUUAQAOo1XNyoA;_ylu=X3oDMTEzM2IxbTdwBGNvbG8DYmYxBHBvcwMxBHZ0aWQDVklQNTc3XzEEc2VjA3Nj
Jean Marie Dangou, head of the World Health Organisation (WHO) in Guinea, said the "Stop Ebola" campaign based on modern communication technology, had all but failed.
"For about one year the main communication strategy was built around media, mainly radio and TV, but it wasn't successful. The country is still dealing with tough and repetitive resistance," Dangou said.
West Africa has recorded some weekly declines in new confirmed cases of Ebola since the start of 2015, but resistance in some communities has undermined efforts to end the epidemic.
The main message from this outbreak is that communication must be adapted to fit the local culture, Dangou said.
Word of mouth may be a better way of getting information out than modern methods in parts of the world where broadcast signals are weak and power for electrical appliances is scarce.
"Lessons learned from Ebola in Guinea can be applied to cholera, malaria or any other infectious disease in other parts of the world that rely on an oral tradition," Dangou added.
At the start of the outbreak, traditional healers were viewed as part of the problem, rather than being recruited to help halt the disease.
"Our communication was top down and the way we delivered the messages was wrong. We told people to stop doing things without explaining why," Dangou told the Thomson Reuters Foundation.
In a shift in policy, community leaders, including healers, are given information and asked to act on it as they see fit. As a result, many have appropriated the "Stop Ebola" messages.
Traditional healers are also supplementing disease surveillance and helping response teams that search for cases.
"Most traditional healers are now aware of the risk of treating Ebola patients. More and more patients are coming to health facilities after a referral from their healer," said Dangou.
A PRICE
Given their important role in efforts to stamp out Ebola, the services of traditional healers should come at a price, said Joseph Souro Mamadouno, 58, a Catholic guérisseur from Macenta.
"Ebola is here today, but it could be cholera tomorrow. We can spread health messages, but the government should cover costs of transport, food and the time we take off work," said Mamadouno, who also works at the local agriculture school.
According to the healers' association, some 2,000 herbal practitioners in Macenta, a district with a population of around 300,000 close to the Liberian border, are out of pocket as a result of the Ebola response.
Ebola shares symptoms with less serious diseases traditional healers say they can treat: fatigue, fever, headache, vomiting and diarrhea. But now these cases are referred to hospitals.
Koly Beavogui, 80, an animist traditional healer from Macenta said she and other female guérisseurs have been reduced to begging for food from neighbors and foraging in the forest.
The scrawny woman, with a wrinkled face and toothless smile, used to treat five to six people a day, but now hardly sees anyone.
"When the sick come to see me, I only ask them to give me whatever they can afford, because we don't buy illness, so we shouldn't have to pay for treatments," said Beavogui, sitting outside her freshly-swept, mudbrick house.
But others are fearful of turning Ebola into an industry.
"I'm not in favor of incentives, because it looks like we are in an Ebola business. These people should become agents of change, in their own community, without any kind of payment," the WHO's Dangou said.
(Reporting by Misha Hussain; Editing by Ros Russell)
? View Comments (2)
Ralson1
Thank you for your message.
Yes I am looking to ski with you in the Dolomites.
You will fell in love with Cortina.
FN
Weedie, I thought of you today,
I' went skiing on one of the most beautiful mountain in the world. Went Down the mountain, shouting GOOOOOOOOOOOOOOOOOOOO NNVC !!!!!!!!!!!!!!!!!!!!!!!!!
Can you feel the vibrations?????
WEST HAVEN, Conn., Jan. 21, 2015 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reported that between January 6 and 13, 2015, Anil Diwan, PhD, the Company's co-founder, President and Chairman, and Dr. Milton Boniuk, an independent member of the Board of Directors, separately purchased NanoViricides common stock in open market purchases, during one of the Company's open trading windows for insiders.
The insider purchases were reported on Form 4's with the Securities and Exchange Commission (SEC) and their combined purchases amounted to 62,392 shares of NanoViricides common stock in uncoordinated open market purchases. During one of the Company's open trading windows for insiders, Dr. Diwan purchased 37,392 shares and independently, Dr. Boniuk purchased 25,000 shares. Shares were purchased at the open market prices ranging between $2.54 and $2.75; prices that Dr. Diwan and Dr. Boniuk believe are a substantial discount to the Company's potential long term value.
For Dr. Diwan, the purchases were made using certain proceeds from the sale of the cGMP facility that was recently sold by Dr. Diwan's special purpose entity Inno-Haven, LLC to the Company, on a costs reimbursement basis, as reported previously. The original purchase of the building prior to extensive renovations was accomplished by Dr. Diwan using his personal savings, loans from other parties, and, in part, from the 10b5-1 sales of his founder shares of the Company's stock in 2011.
"Continuing purchases by insiders is a sign of confidence in the future of the Company," said Eugene Seymour, MD, MPH, Chief Executive Officer, "and reflects the on-going progress towards our goal of getting our drugs into humans as soon as possible."
I would here venture the opinion that all this was well underway BEFORE USAMRIID even started their testing!!!!
I loved all those movies.
Charles Bronson is my favorite actor.
This is a question to ask him.
OK - then when do you think we will hear them?
It all depends on the agreements they have made.
That we haven't yet heard is that a good sign or not??
Yes this can be a good sign, because I think it takes time to put everything in place. And I think that they will write the PR once all the agreements will be taken.
Tweaking?
PR formatting?
Exactly.
Financing/grants being arranged???
Yes, and it will take some time.
I understood your explanation, I just didn't ask for it. I asked for his explanation. Your volunteer work is only helpful if you were able to read his mind before you provided it.
Let them speak, please
I meant to say that I think the company has the results of the tests on Ebola.
At this time they must be talking.
$100 in 2018.
They had the material ready and were waiting until the request was made!
NanoViricides Files Quarterly Report for Period Ending 2014-12-31
The Company estimates that it now has approximately $36.4 Million (M) of current assets plus restricted cash (cash, cash equivalents, collateral advance, prepaid expenses, and security deposits) as of December 31, 2014, the end of the reporting quarter. The Company's operating expenditure during this quarter was approximately $1.9M. Shareholder equity stood at approximately $30.5M for the quarter.
The Company reports that all of its drug development programs are progressing satisfactorily and that it will continue to provide updates as appropriate.
In particular, the Company has reported that its anti-Ebola nanoviricide® drug candidates have been sent for testing at a prestigious BSL4 facility in the United States, subsequent to the end of the reporting period. These candidates were designed and synthesized in less than four months utilizing our rapid drug development platform. The Company has previously reported that it has signed a "Cooperative Research and Development Agreement - Materials Transfer Agreement (CRADA-MTA)" with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) for biological testing of its anti-Ebola drug candidates. The Company has the ability to produce sufficient quantities of a successful drug candidate for potential field use.
The Company has previously reported that it completed the acquisition of the state-of-the-art nanomedicines manufacturing facility at 1 Controls Drive, Shelton, CT, from Inno-Haven, LLC, by reimbursing Inno-Haven for the costs incurred. This facility will be capable of producing any of the Company's drug candidates in a cGMP-compliant manner in multi-kilogram quantities. This facility will be able to provide the cGMP clinical drug substances for the Company's future human clinical studies. ("c-GMP"= current Good Manufacturing Practices).
The Company has previously reported that the initial safety and toxicology studies of FluCide" in a rat model were completed at BASi, Inc., subsequent to the reporting period. These studies have continued to demonstrate an excellent safety profile for our injectable FluCide drug candidate, at doses up to 300mg/kg given for 14 days (total 4,200mg/kg).
In addition, the Company is performing process development and scale up studies on its FluCide drug candidate. FluCide is designed as a treatment for influenza in seriously ill hospitalized patients, a potentially fatal disease for which no satisfactory treatment exists. FluCide's excellent safety profile resulted in the need for a very large quantity of the drug for the GLP Safety/Toxicology studies required for an Investigational New Drug ("IND") filing. The multi-kilogram quantities of FluCide needed for these safety and toxicology studies will be produced in the new Shelton facility.
The Company estimates that the cash in hand is sufficient to enable us to perform initial human clinical trials of our injectable FluCide" drug candidate, as well as possibly to advance another drug candidate towards initial human clinical trials. As previously reported, our strong cash position has enabled us to restart our anti-Ebola drug development program in response to the current epidemic. The Company's estimates are based on its current rate of expenditure and also on certain approximate estimates for clinical development of its drug candidate as gleaned from discussions with various contract research organizations.
The Company reports that it has successfully transitioned to Eisner-Amper LLP as our new external auditing firm with this quarterly report. During this transition, it was discovered that the Company had inadvertently treated certain warrants issued in relation to the registered direct offerings in September 2013 and in January 2014, and a certain Debenture issued in July 2014, without considering potential derivative effects related to the terms of these instruments. Upon finding this omission, and determining that this required restatement of certain previously filed reports, the Company filed a current report on Form 8-K that the previously issued Annual Report for the period ending June 30, 2014, and the recently issued quarterly report for the period ending September, 30, 2014, could not be relied upon.
The corresponding restated annual report and the restated quarterly report were filed on February 23, 2014. The restatements only affected the derivative treatment of certain warrants and certain terms of the debenture referenced above. The Company has taken steps to improve its internal controls to avoid such issues in the future. However, the excessive workload associated with these restatements and the transition from the previous audit firm to the new external audit firm led to late filing by one day of the Company's filing of the quarterly report for the period ending December 31, 2014.
On Italian TV
20 new cases with ebola in Sierra Leone.
Some of them died
Thanks Echo for that news .
Soon we will got more news about EbolaCide2
Then the company will ship more flucides to get tested, and we already knows how successful that drug has been so far
NNVC has a lot going on now. And this is only February.
Stay tuned for the next PR coming soon.
FN
Ebolacide2 results could be in the next few days.
Stay tuned.
FN
Next week is very possible.
I can count on you Weedie